Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
  1. Home
  3. Landscape And Prognostic Significance Of Oncogene Drivers In Metastatic Castration Sensitive Prostate Cancer.
  1. Home
  3. Landscape And Prognostic Significance Of Oncogene Drivers In Metastatic Castration Sensitive Prostate Cancer.

Related Experiment Video

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.

Theodore Wang1, Jongmyung Kim1, Ritesh Kumar1

  • 1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Translational Cancer Research
|December 19, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Oncogene mutations are common in metastatic castration-sensitive prostate cancer (mCSPC) and linked to worse outcomes. These findings may help personalize treatment for advanced prostate cancer.

Keywords:
Prostate cancermetastatic castration sensitiveoncogene

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Related Experiment Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Area of Science:

  • Oncology
  • Genetics
  • Prostate Cancer Research

Background:

  • Tumor suppressors are established drivers of cancer invasion and metastasis in metastatic castration-sensitive prostate cancer (mCSPC).
  • The frequency and prognostic significance of oncogene alterations in mCSPC remain unclear.
  • Understanding oncogene mutations is crucial for comprehending prostate cancer progression.

Purpose of the Study:

  • To investigate the spectrum of oncogene mutations in mCSPC.
  • To determine the prognostic impact of these oncogene alterations on patient outcomes.
  • To identify potential targets for personalized therapy in advanced prostate cancer.

Main Methods:

  • Next-generation sequencing was performed on 477 mCSPC patients.
  • Oncogene alterations were identified in a panel of 23 genes.
  • Radiographic progression-free survival (rPFS), time to castration-resistant prostate cancer (tdCRPC), and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression models.

    • Main Results:

    • Approximately 24.5% of patients (117/477) had oncogene mutations, with MYC, PIK3CA, and CTNNB1 being the most frequent.
    • Oncogene mutations were associated with significantly inferior rPFS, tdCRPC, and OS.
    • Multivariable analysis confirmed oncogene mutations as a strong predictor of accelerated development of castration-resistant prostate cancer (CRPC).

    Conclusions:

    • Oncogene mutations are frequently observed in mCSPC and correlate with aggressive disease features.
    • These genetic alterations portend poorer clinical outcomes, including shorter survival.
    • Further validation is needed to integrate these findings into personalized treatment strategies for mCSPC.